Inhibition of inflammatory pain by activating B-type natriuretic peptide signal pathway in nociceptive sensory neurons

J Neurosci. 2010 Aug 11;30(32):10927-38. doi: 10.1523/JNEUROSCI.0657-10.2010.

Abstract

B-type natriuretic peptide (BNP) has been known to be secreted from cardiac myocytes and activate its receptor, natriuretic peptide receptor-A (NPR-A), to reduce ventricular fibrosis. However, the function of BNP/NPR-A pathway in the somatic sensory system has been unknown. In the present study, we report a novel function of BNP in pain modulation. Using microarray and immunoblot analyses, we found that BNP and NPR-A were expressed in the dorsal root ganglion (DRG) of rats and upregulated after intraplantar injection of complete Freund's adjuvant (CFA). Immunohistochemistry showed that BNP was expressed in calcitonin gene-related peptide (CGRP)-containing small neurons and IB4 (isolectin B4)-positive neurons, whereas NPR-A was present in CGRP-containing neurons. Application of BNP reduced the firing frequency of small DRG neurons in the presence of glutamate through opening large-conductance Ca2+-activated K+ channels (BKCa channels). Furthermore, intrathecal injection of BNP yielded inhibitory effects on formalin-induced flinching behavior and CFA-induced thermal hyperalgesia in rats. Blockade of BNP signaling by BNP antibodies or cGMP-dependent protein kinase (PKG) inhibitor KT5823 [(9S,10R,12R)-2,3,9,10,11,12-hexahydro-10-methoxy-2,9-dimethyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid methyl ester] impaired the recovery from CFA-induced thermal hyperalgesia. Thus, BNP negatively regulates nociceptive transmission through presynaptic receptor NPR-A, and activation of the BNP/NPR-A/PKG/BKCa channel pathway in nociceptive afferent neurons could be a potential strategy for inflammatory pain therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analysis of Variance
  • Animals
  • Antibodies / pharmacology
  • Antibodies / therapeutic use
  • Biophysical Phenomena / drug effects
  • Biophysical Phenomena / physiology
  • Calcitonin Gene-Related Peptide / metabolism
  • Carbazoles / pharmacology
  • Carbazoles / therapeutic use
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Enzyme Inhibitors / pharmacology
  • Enzyme Inhibitors / therapeutic use
  • Excitatory Postsynaptic Potentials / drug effects
  • Freund's Adjuvant
  • Ganglia, Spinal / pathology
  • Gene Expression Regulation / drug effects
  • Gene Expression Regulation / physiology*
  • Glutamic Acid / pharmacology
  • Hyperalgesia / complications
  • Hyperalgesia / drug therapy
  • Inflammation / chemically induced
  • Inflammation / complications
  • Lectins / metabolism
  • Male
  • Membrane Potentials / drug effects
  • Membrane Potentials / physiology
  • Natriuretic Peptide, Brain / immunology
  • Natriuretic Peptide, Brain / metabolism*
  • Pain / drug therapy
  • Pain / etiology
  • Pain / metabolism*
  • Pain Measurement / methods
  • Patch-Clamp Techniques / methods
  • Peptides / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Atrial Natriuretic Factor / metabolism
  • Sensory Receptor Cells / drug effects
  • Sensory Receptor Cells / metabolism*
  • Signal Transduction / drug effects
  • Signal Transduction / physiology*
  • Time Factors

Substances

  • Antibodies
  • Carbazoles
  • Enzyme Inhibitors
  • Lectins
  • Peptides
  • Natriuretic Peptide, Brain
  • KT 5823
  • Glutamic Acid
  • iberiotoxin
  • Freund's Adjuvant
  • Receptors, Atrial Natriuretic Factor
  • atrial natriuretic factor receptor A
  • Calcitonin Gene-Related Peptide